The anticholinergic cognitive burden (ACB) scale scores each medication 1, 2, or 3 for anticholinergic activity, so a patient's total load can be calculated by simple addition. A cumulative ACB score of 3 or more is the widely used threshold associated with impaired memory, slower processing, and increased delirium risk in older adults — even when no single drug looks dangerous on its own.

Psychiatrists prescribers see anticholinergic load everywhere: amitriptyline for sleep, oxybutynin for an over-the-counter-style bladder problem, a nighttime diphenhydramine "PM" product, paroxetine in a patient who tolerates it well. Each one scores low-to-moderate in isolation; together they quietly erode cognition. This guide explains what the ACB scale measures, the anticholinergic effects to look for at the bedside, commonly cited scores for psychiatric and GP drugs, and how to run a deprescribing review that actually reduces the burden.

What is the anticholinergic cognitive burden scale?

The ACB scale was developed by Boustani and colleagues to give clinicians a quick, evidence-informed way to quantify anticholinergic exposure without needing plasma levels or pharmacology lookups. Each drug receives a score: 1 for mild, 2 for moderate, and 3 for strong anticholinergic activity, based on the published evidence of its muscarinic receptor effects. The scores are additive, so a patient taking amitriptyline (3), paroxetine (1), and oxybutynin (3) carries a total ACB of 7 — substantial burden from three prescriptions that each looked reasonable when written.

Why the numbers matter: cumulative burden, not any single agent, tracks with outcomes. Observational work on anticholinergic exposure — including the ACB scale literature on PubMed — has repeatedly linked higher total scores to worse memory and processing speed in older adults, incident cognitive impairment and dementia risk, higher rates of delirium, falls, and increased mortality. Guidelines including NICE's multimorbidity guidance explicitly recommend reviewing anticholinergic burden as part of medication review in older people. Note the scale measures a drug's intrinsic anticholinergic activity — it does not capture other anticholinergic-like effects such as sedation, so an antihistamine can be sedating while scoring 0 on the ACB scale.

The anticholinergic effects to recognise at the bedside

The classic peripheral constellation is easy to spot once you look for it: dry mouth (often the earliest and most missed sign — patients think it is "just ageing" or diabetes), constipation and reduced gut sounds, urinary retention with overflow, blurred vision from cycloplegia and mydriasis, tachycardia, and reduced sweating with heat intolerance. Ask directly: "Have you noticed a dry mouth, trouble passing urine, or becoming more constipated lately?" Patients rarely volunteer these.

The central effects are the reason the scale exists. In older adults, rising ACB load shows up as inattention and fluctuating confusion (delirium), sluggish recall, word-finding difficulty, worse executive function, daytime sedation, low mood flattening, and — in overdose or extreme burden — anticholinergic toxicity with agitation, hallucinations, hyperthermia, and mydriasis ("blind as a bat, mad as a hatter, hot as a hare, red as a beet, dry as a bone"). The trap is that insidious cognitive decline gets labelled neurodegeneration or "ageing" when a medication review would have been the intervention.

High-yield

"New confusion" in an elderly patient on multiple drugs: count the ACB load before assuming dementia. Tally every prescription, over-the-counter antihistamine, sleep aid, and bladder drug, calculate the total, and treat the reversible causes — delirium from anticholinergics often clears within days of stopping the culprit. Always cross-check with your local formulary before changing anything.

Common psychiatric and GP drugs with their ACB scores

These are the commonly published ACB values from the Boustani scale and its derivatives — conservative figures you can quote in exams and handovers. The "where it hides" column is the clinically useful part: the burden usually comes from the drug nobody remembered prescribing.

Drug ACB score Where the burden hides
Amitriptyline 3 Low-dose "for sleep" or neuropathic pain — the classic hidden load
Doxepin 3 Prescribed at low dose specifically for insomnia
Clomipramine 3 OCD treatment — strong antimuscarinic plus noradrenergic effects
Oxybutynin 3 Overactive bladder — frequently added by primary care, rarely reviewed
Diphenhydramine 3 OTC "PM" sleep and allergy products — patients don't list these
Paroxetine 1 SSRI with the most antimuscarinic activity in its class
Citalopram 1 Some lists score it 0 — check your local version of the scale
Sertraline 0 Typical low-burden SSRI switch target

Reading the table as an exam answer: total ACB ≥3 is the threshold most commonly cited for clinically meaningful cognitive risk, and taking two or more anticholinergic drugs simultaneously is itself a red flag regardless of the individual scores. Scores can vary slightly between published versions of the scale — state the version you are using and always check the current formulary.

Deprescribing: how to reduce the anticholinergic load

Run the review as a structured medication reconciliation, not a casual tidy-up. List every prescription, over-the-counter product, and herbal remedy; score each one; add the total; then attack the highest scores first, because removing one ACB-3 drug usually cuts the burden more than three ACB-1 swaps ever will. For each candidate, ask: is the indication still active, is there a lower-burden alternative, and can anything simply be stopped? One change at a time where possible, with a clear review date — cognitive benefits of reduction often appear within weeks, and getting an anticholinergic effect back tells you which drug was doing the damage.

Common swap suggestions in psychiatry practice: paroxetine → sertraline or citalopram (typically lower antimuscarinic activity), amitriptyline for sleep or pain → a genuinely low-anticholinergic alternative such as a gabapentinoid, duloxetine, or melatonin depending on indication — follow your formulary and the underlying condition. For overactive bladder, tolterodine or mirabegron-type options may score lower than oxybutynin, subject to local guidance. Replace diphenhydramine sleep aids with sleep-hygiene measures or a non-anticholinergic agent. Crucially, never stop an antidepressant abruptly — taper, monitor for discontinuation syndrome and relapse, and time changes around your risk assessment.

For trainees, this is exactly the kind of integrated psychopharmacology reasoning that separates a pass from a top score: name the drug, name its receptor profile, quantify the load, propose the alternative. Preppsy's spaced-repetition flashcards are built around facts like these — ACB scores, swap pairs, and the receptor traps examiners love.

Frequently asked questions

What is the anticholinergic cognitive burden scale used for?

The ACB scale quantifies how strongly each of a patient's medications blocks muscarinic acetylcholine receptors, scoring them 1 for mild, 2 for moderate, and 3 for strong activity. Scores are added to give a total anticholinergic load, which clinicians use to identify patients — especially older adults — whose cumulative exposure may be contributing to confusion, delirium, falls, or cognitive decline.

What ACB score is considered high risk?

A total score of 3 or more is the most widely cited threshold for increased risk of cognitive impairment, delirium, and functional decline. Some services also flag any patient taking two or more anticholinergic drugs simultaneously, since the effects are additive — one score-3 drug reaches the threshold alone.

Which psychiatric medications have the highest anticholinergic burden?

The tricyclics dominate: amitriptyline, doxepin, and clomipramine all score 3, as do oxybutynin and diphenhydramine. Among antidepressants, paroxetine carries the most anticholinergic activity at a score of 1, while sertraline is commonly listed at 0 — which is why sertraline is a frequent switch target from paroxetine in older patients.

Can reducing anticholinergic burden reverse cognitive symptoms?

In many cases, yes — anticholinergic cognitive effects are often dose-dependent and partially reversible. Delirium from a newly added anticholinergic typically clears within days of stopping it, and slower cognitive symptoms frequently improve over weeks after a load reduction. Chronic exposure, however, may leave residual deficits, which is why deprescribing works best as early review rather than rescue.

Key takeaways

  • The ACB scale scores each drug 1–3; the scores are additive, and a total of ≥3 is the commonly cited risk threshold.
  • Classic anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision — plus central confusion, sedation, and delirium in older adults.
  • The biggest culprits are amitriptyline, doxepin, clomipramine, oxybutynin, and diphenhydramine (all 3), with paroxetine at 1.
  • The danger is cumulative load: three individually "fine" drugs can total a dangerous burden.
  • Deprescribe by attacking the highest score first, swapping paroxetine for sertraline where appropriate, and reviewing OTC sleep and allergy products patients forget to mention.
  • "New confusion" in an elderly patient on multiple medications — calculate the ACB total before diagnosing dementia.

The ACB scale turns a vague worry about "too many tablets" into a number you can act on — score the list, cut the biggest contributor, and reassess cognition. If you are building your psychopharmacology revision around high-yield facts like these, see Preppsy's plans and put the receptor-level detail on autopilot.

Cover image: “The Anticholinergic Burden Scale (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.